The prevalence of venous leg ulceration (VLU) in the adult population is up to 3% with higher prevalence seen with increasing age and female gender. Active ulceration has a profound detrimental effect upon the quality of life and is associated with significant pain and mobility restriction limiting a patient's physical and social roles. Mean lifetime with a venous ulcer is between 5-10 years. 1-3% of the western healthcare budget is spent on managing this condition because of its chronic and relapsing nature. 1, 2 The gold standard of care until now for VLU has been compression bandaging with initial ulcer healing rates in excess of 70% at six months, but subsequently 25% of these ulcers recur by one year. The Effect of Surgery and Compression on Healing And Recurrence (ESCHAR) trial from the late 1990s showed that ulcer recurrence was significantly reduced for patients who had superficial venous surgery in combination with compression therapy compared to those who had compression alone (31% vs. 56% leg ulcer recurrence at four years) but did not show improved ulcer healing rate. 3 A number of factors may have reduced the benefit of surgery on overall time to achieve ulcer healing in this landmark trial. One perception was the lack of statistical power in which participants with healed rather than open active ulcers predominated. The analysis was performed on an intention to treat principle and 19% of those randomized to the surgery arm did not receive an intervention, because a lot of patients with venous ulcer disease were elderly with significant co-morbidities and were deemed not fit for a general anaesthetic. In those who underwent surgery, the majority did not have their superficial venous reflux eliminated, and perforator disease was not primarily treated because of the limitations of open surgery. Furthermore, surgery was delayed on average for 7 weeks out of the 24-week ulcer healing phase of the study. This led to a widely held view until now that superficial venous surgery can be deferred until the leg ulcer had healed and on the grounds of increased risk of wound infection, although the ESCHAR trial only showed a 2% wound infection rate in those treated with surgery.
The recent publication of the primary results of the Early Venous Reflux Ablation (EVRA) multicentre trial has changed the VLU landscape and will renew the interest for early ablation of superficial venous reflux for CEAP 6 disease. 4 The world of VLU enthusiasts has finally gained significant Level 1 evidence that has the potential to change the clinical practice worldwide. EVRA was a non-commercial study conducted at 20 National Health Service (NHS) hospitals across the UK and randomised 450 patients with active venous ulceration of less than six months duration to two groups; the first to receive therapeutic compression therapy and early endovenous ablation of their superficial venous reflux within two weeks of randomisation and the other group to receive compression alone. This group received deferred endovenous intervention once the ulcer was healed. Those who had early endovenous intervention as an adjunct to compression therapy demonstrated faster healing time, rate of ulcer healing at six months, median ulcer-free time and decreased recurrence of their VLU. The investigators are to be congratulated on a monumental effort over the past five years, culminating in a landmark trial in vascular surgery, which will likely be a game changer and have a global impact as to how venous ulcers should now be treated -patients should have an expedited vascular assessment and offered early intervention to ablate their superficial venous reflux. Patient and care provider education is now essential. This is borne out by the fact that the most significant reason for exclusion into the study was ulcer presence exceeding six months in 27% patients screened, which raises questions about the variation in the quality of the wound care centres and allied professionals/patient perception of the condition and how it should be treated before it reaches specialist care. As acknowledged by the authors, pathways and models of care for VLU need to be developed and standardised to allow for early assessment and treatment of superficial venous reflux. A multi-disciplinary of specialists also need to be involved with the subsequent care of the wound, dressings and social mobility of the patient.
The commonest form of endovenous treatment used was ultrasound-guided foam sclerotherapy (FS) -nearly 50% -followed by endothermal ablation. Reason(s) for choosing FS as the first line treatment are unclear but being a pragmatic trial with real world target primary and secondary endpoints will likely reflect the versatility, acceptability and relatively cheap cost of this endovenous ablative modality, which can be used in elderly patients under local anaesthetic and in the outpatient setting. However, the anatomical and clinical recurrence rates associated with this form of intervention have been shown to be the highest amongst the different ablative modalities. 5 Furthermore, endothermal techniques may not be able to get down to the lowest points of saphenous venous reflux because of the risk of nerve injury potentially leaving incompetent perforators still feeding the VLU. The newer forms of non-thermal nontumescent technologies (NTNT) 6 were seldom employed and may be due to a cost issue or the devices being unavailable in the NHS setting. The advantages of an NTNT device would be to obviate the need to push the saphenous vein off the skin surface during the tumescence process to avoid cutaneous burns. Furthermore, dealing with below knee venous reflux using a device not requiring thermal energy would prevent saphenous/sural nerve injury. Also, minimizing the use of tumescence below the knee, especially with poor quality skin or active ulceration, is an obvious advantage. These venous devices lend themselves quite nicely because they can be delivered from a retrograde position to the ulcer base. 7 Would this lead to lower rates of deep vein thrombosis and secondary infection following the procedure, which are always the concerns during active ulceration? Analysis of results by treatment modality would be interesting and would certainly help in deciding on the endovenous treatment offered for the management of the VLU patient.
One of the most impressive aspects of the trial was the provision of high-quality compression therapy and patient compliance rate, which may well explain the high rates of ulcer healing in both treatment arms. This is usually not the case outside a randomized controlled trial and in the hotter tropical climates, which may well explain the slower healing times of ulcers in the real-world setting. Therefore, the effect of early endovenous ablation in ulcer healing may well be magnified in daily clinical practice than was seen in EVRA, because the reliance on compression and patient adherence would be much less.
Professor Davies and his team should be congratulated on successfully executing such a relevant venous trial, that will likely result in a change of practice in VLU patients. National and international guidelines will need to be changed to reflect the results of this study.
